Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | TFPI | P10646 | 3/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.50 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783034 | 0.85 | OPRM1 (0.53) | OPRM1OPRK1CXCR4KEAP1TFPI | |
| SCHEMBL30085017 | 0.84 | CXCR4 (0.60) | OPRM1OPRK1CXCR4KEAP1TFPI | |
| SCHEMBL30842181 | 0.83 | NMUR2 (0.64) | OPRM1CXCR4TFPIEPHA2NMUR2 | |
| SCHEMBL30176437 | 0.83 | TFPI (0.64) | CXCR4TFPIEPHA2NMUR2NMUR1 | |
| SCHEMBL30176414 | 0.83 | TFPI (0.64) | CXCR4TFPIEPHA2NMUR2NMUR1 | |
| SCHEMBL29783021 | 0.83 | OPRM1 (0.54) | OPRM1OPRK1KEAP1EPHA2NMUR2 | |
| SCHEMBL8067075 | 0.83 | NMUR2 (0.58) | OPRM1OPRK1CXCR4TFPINMUR2 | |
| SCHEMBL8067081 | 0.83 | NMUR2 (0.58) | OPRM1OPRK1CXCR4TFPINMUR2 | |
| SCHEMBL30834921 | 0.83 | NMUR2 (0.65) | OPRM1OPRK1KEAP1TFPIEPHA2 | |
| SCHEMBL30804665 | 0.83 | TFPI (0.59) | OPRM1OPRK1CXCR4TFPINMUR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4605008-A1 | ALPHA-V BETA-6 INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2024129931-A1 | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4370136-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023288045-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ADAR, ADA, NUDT1 | OPRM1 2519/4885OPRK1 3222/4885CXCR4 1927/4885 |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | OPRM1 631/4885OPRK1 1253/4885CXCR4 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.